CD8 CD28 regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.

Christoph Mann, Hartmut Goldschmidt, Ullrich Graeven, Katharina Kriegsmann, Carsten Müller-Tidow, Jan Dürig, Stephan Kremers, Andrea Seidel-Glätzer, Britta Besemer, Niels Weinhold, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Christian Kunz, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, Michael Hundemer, Christof Scheid, Peter Reimer, Roland Fenk, Manfred Hensel, Axel Benner, Uwe M Martens, Rolf Mahlberg, Elias K Mai, Uta Bertsch, Stefanie Huhn, Katja C Weisel, Markus Munder, Dirk Hose, Marc S Raab, Igor W Blau, Mathias Hänel, Hans J Salwender, Anna Jauch

Journal: Leukemia 2024;38(7):1621-1625

PMID: 38830959

Abstract

Address: Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Laborarztpraxis Rhein-Main MVZ GbR, Frankfurt am Main, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany.; Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.; Department of Hematology, Oncology and Immunology, Phillips-University Marburg, Marburg, Germany.; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.; Department of Hematology, Oncology, Ruhr-University Bochum, Bochum, Germany.; Department of Internal Medicine II, University Hospital Frankfurt a.M., Frankfurt a.M., Germany.; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Hematology/Oncology Center, Koblenz, Germany.; Evang. Kliniken Essen-Mitte, Evang. Krankenhaus Essen-Werden, Essen, Germany.; Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany.; Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.; Hematology/Oncology Center, Lebach, Germany.; Hematology, Oncology, Palliative Care, SLK Clinics Heilbronn, Heilbronn, Germany.; Hematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany.; Mannheimer Onkologie Praxis, Mannheim, Germany.; Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany.; Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.